Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.The following content may not be associated with Alnylam Pharmaceuticals. Prior to Pfizer, Yvonne held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President and Chief of Strategy for Research and Development, Senior Vice President for Medicines Development and Chief Medical Officer for Europe.Dr.
He is a member of the Board for Agios Pharmaceuticals and Biotechnology Industry Organization (BIO) Board, and is a member of the BIO Executive Committee.Dr.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.The following content may not be associated with Alnylam Pharmaceuticals. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.The following content may not be associated with Alnylam Pharmaceuticals. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.You are now being directed to another Alnylam website that containsYou are now being directed to another Alnylam website that containsThe following content may not be associated with Alnylam Pharmaceuticals. Akin Akinc joined Alnylam in 2003 and is currently Vice President and General Manager of the givosiran program. Links to all outside sites are provided as a reference for our visitors. Our RNAi therapies leverage two distinct approaches to enable delivery of small interfering Ribonucleic Acid (siRNA): lipid nanoparticles (LNP) and GalNAc-conjugates.Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, hypercholesterolemia, and primary hyperoxaluria type 1.
Links to all outside sites are provided as a reference for our visitors. We are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases. He is a Fellow of the Royal College of Physicians, U.K. Akshay is a member of the Board of Directors for Editas Medicine Inc and Scholar Rock Inc. From 2014-2018, he served a Board member of Visterra, Inc.Eric Green joined Alnylam in 2015 and is currently Senior Vice President and General Manager of the TTR program, comprised of ONPATTRO (patisiran) and Vutrisiran.

Links to all outside sites are provided as a reference for our visitors.